Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 12/20 | 0.42 |
| ▸ | DRD3 | P35462 | 9/20 | 0.42 |
| ▸ | DRD4 | P21917 | 7/20 | 0.42 |
| ▸ | DRD1 | P21728 | 4/20 | 0.42 |
| ▸ | DRD5 | P21918 | 4/20 | 0.42 |
| ▸ | HTR1D | P28221 | 2/20 | 0.36 |
| ▸ | HTR5A | P47898 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1712875 | 0.85 | DRD2 (0.43) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL5599606 | 0.80 | CA1 (0.50) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL29414143 | 0.80 | CA1 (0.50) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL1713611 | 0.79 | DRD2 (0.40) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL29607374 | 0.79 | DRD2 (0.40) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL28142221 | 0.78 | DRD2 (0.39) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL30706241 | 0.77 | DRD2 (0.42) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL30665126 | 0.77 | DRD2 (0.42) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL28726740 | 0.77 | CXCR2 (0.44) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL2984151 | 0.77 | DRD2 (0.42) | DRD2DRD3DRD4DRD1DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115746046-A | O-silyl substituted phenyl sulfonate and synthesis method and application thereof | 杭州瀛拓科技有限公司 | 2023-03-07 | — | — | CN | disclosed |
| CN-114269717-A | Catalytic cannabinoid processes and precursors | 凯尔化学科技公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20140288040-A1 | SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION | ASTEX THERAPEUTICS LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
| US-20140288040-A1 | SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION | ASTEX THERAPEUTICS LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
| US-20140288040-A1 | SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION | ASTEX THERAPEUTICS LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
| EP-2773613-A1 | SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION | Astex Therapeutics Limited (GB) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013064538-A1 | SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013064538-A1 | SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288040-A1 | SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION | NR1H4, CFH, SLC10A1 | DRD2 850/4885DRD3 859/4885DRD4 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.